In both our subgroup analysis and our analyses using the activity score, most associations identified in the main analyses remained significant, suggesting that any effects of CYP2C19 genotypes on the responses to citalopram, escitalopram, and sertraline are linked to metabolic capacity and are independent of depression status. This evidence concerns the gene CYP2C19 and depressive symptom measurement.